Drug General Information (ID: DDIOQK2LU7)
  Drug Name Measles virus vaccine live attenuated Drug Info Emapalumab Drug Info
  Drug Type Vaccine Monoclonal antibody
  Therapeutic Class Vaccine Selective Immunosuppressants

 Mechanism of Measles virus vaccine live attenuated-Emapalumab Interaction (Severity Level: Major)
     Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Measles virus vaccine live attenuated Emapalumab
      Mechanism Vaccine or toxoid Immunosuppressive effects
      Key Mechanism Factor 1
Factor Name Vaccine/toxoid
Factor Description The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response.
      Mechanism Description
  • Antagonize the effect of Measles virus vaccine live attenuated when combined with Emapalumab 

Recommended Action
      Management The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.

References
1 Product Information. Gamifant (emapalumab). Sobi Inc, Ardmore, PA.